Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable …

…, JT Brandt, JA Jakubowski, H Naganuma… - European heart …, 2006 - academic.oup.com
Aims This study was designed to compare the degree of inhibition of platelet aggregation (IPA)
of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery …

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

…, NA Farid, DS Small, JA Jakubowski, H Naganuma… - American heart …, 2007 - Elsevier
BACKGROUND: The aim of this study was to compare rate of onset, magnitude, and consistency
of platelet inhibition after administration of prasugrel or clopidogrel and to relate platelet …

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

…, KJ Winters, H Naganuma… - Cardiovascular drug …, 2007 - Wiley Online Library
Prasugrel (CS‐747, LY640315) is a novel member of the thienopyridine class of oral antiplatelet
agents that includes ticlopidine and clopidogrel. Like other thienopyridines, prasugrel is …

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

…, N Matsushima, F Asai, H Naganuma… - British journal of …, 2007 - Wiley Online Library
Aims This double‐blind, placebo‐controlled trial was designed to evaluate the pharmacodynamics,
pharmacokinetics, safety, and tolerability of prasugrel (CS‐747, LY640315), a novel …

Brain insulin impairs amyloid-β (1-40) clearance from the brain

…, S Ohtsuki, A Kurihara, H Naganuma… - Journal of …, 2004 - Soc Neuroscience
Cerebral amyloid-β peptide (Aβ) clearance plays a key role in determining the brain level of
Aβ; however, its mechanism remains unclear. In this study, we investigated cerebral Aβ …

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

F Asai, JA Jakubowski, H Naganuma, JT Brandt… - Platelets, 2006 - Taylor & Francis
We assessed the tolerability, pharmacodynamics as measured by inhibition of platelet
aggregation (IPA), and pharmacokinetics of prasugrel (CS-747, LY640315), a novel …

The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects

…, NA Farid, DS Small, H Naganuma… - Journal of …, 2006 - journals.lww.com
Prasugrel (CS-747, LY640315), a novel thienopyridine, is a potent and orally active
antiplatelet agent in vivo. The aims of this double-blind, double-dummy, placebo-controlled, …

Species differences in the transport activity for organic anions across the bile canalicular membrane

H Ishizuka, K Konno, T Shiina, H Naganuma… - … of Pharmacology and …, 1999 - ASPET
Species differences in the transport activity mediated by canalicular multispecific organic
anion transporter (cMOAT) were examined using temocaprilat, an angiotensin-converting …

Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai …

H Ishizuka, K Konno, H Naganuma, K Sasahara… - … of Pharmacology and …, 1997 - ASPET
Temocapril · HCl (α-{(2S,6R)-6-[(1S)-1-ethoxy-carbonyl-3-phenyl-propyl]amino-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4yl}acetic
acid hydrochloride) is a novel prodrug of an …

Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status

…, CD Payne, J Zhu, MR Warner, H Naganuma… - The American journal of …, 2007 - Elsevier
Failure to achieve an adequate level of platelet inhibition during percutaneous coronary
intervention is associated with an increased risk for periprocedural myocardial injury. This study …